Walmart GLP 1 coverage makes Ozempic and Mounjaro free for diabetes but not for weight loss

Walmart GLP 1 coverage will change in 2027 in a way that splits workers by diagnosis. The retailer told staff that Ozempic and Mounjaro will cost nothing for eligible employees with type 2 diabetes under most of its medical plans, while the same drugs prescribed only for weight loss stay outside the plan. The change came in an October 13 letter to employees and lands as many large US employers rethink what they will pay for.

What Walmart changes for 2027

The letter came from Donna Morris, the chief people officer, and went to a US workforce of about 1.6 million people, according to Fox Business. It lists more than 250 prescription drugs that will cost employees nothing under most Walmart medical plans from 2027, including certain insulin products and inhalers. SHRM reported that Ozempic and Mounjaro are on that no cost list for eligible workers with type 2 diabetes, and that each prescription will need a new prior authorization before the zero price applies. In practice a prescriber has to send the plan proof of the diagnosis first. Open enrollment runs until November 6, so workers are choosing a plan for the coming year right now.

The limit of the new Walmart GLP 1 coverage is plain. According to SHRM, the company will not pay for Ozempic or Mounjaro when a doctor prescribes either drug solely for weight loss, so a worker with obesity but no diabetes diagnosis sees no change from the new list. Other parts of the package move money the other way. Reuters, citing the company website, reported that the premium for the starting medical plan rises by $1.50 per biweekly pay period, to $39.80. Walmart also widened free specialist reviews and added paid leave for parents of babies in neonatal intensive care. The company did not publish an estimate of what the drug changes will cost it or how many workers they reach.

Why employers split diabetes and weight loss

Walmart is not alone in drawing this line. In SHRM's 2026 benefits survey, 47% of employers that answered paid for GLP 1 drugs used for type 2 diabetes, against 15% for weight management. In July, the International Foundation of Employee Benefit Plans counted 60% of employers covering the drugs for diabetes only, up from 55% in 2025, while 36% covered both uses, the same share as a year earlier. Every count shows the same pattern: diabetes treatment is handled as a medical need, and weight loss coverage as an optional extra that a plan can refuse. For Walmart workers, the diagnosis on the prescription now decides whether the monthly bill is zero or the full price.

For Walmart workers, the diagnosis on the prescription now decides whether the monthly bill is zero or the full price.

Cost is the reason employers give most often. SHRM cites KFF data showing that about one in eight US adults now take a GLP 1 drug, and says brand name injections typically cost $1,000 to $1,500 a month, with employers paying 70% to 100% of that bill. "At the end of the day, the biggest issue is cost," said Eileen Pincay, pharmacy practice leader at the consultancy Segal. She contrasted the drugs with metformin, a cheap older medicine that has never caused this kind of debate. Because people may stay on these medicines for years, a plan that covers weight loss takes on a large bill with no clear end date, which is why many sponsors keep only the diabetes use.

Employer GLP 1 coverage is shrinking for obesity

The wider trend in employer GLP 1 coverage points down for weight loss. The Business Group on Health surveyed 127 large employers covering 8.7 million people in the United States and found that coverage of the drugs for obesity fell from 72% in 2025 to 60% in 2026. In the same survey, 14% said they had already dropped or planned to drop weight management coverage by 2027, and 24% had never offered it and were not considering it. Starbucks has said it will stop covering GLP 1 drugs prescribed for weight loss for its benefits eligible staff. The picture differs abroad, where Canadian employer coverage of the drugs for weight loss has risen.

Some employers look for middle paths instead of a flat yes or no. SHRM chief executive Johnny C. Taylor described plans that cover both uses with different deductibles, and others that pay only on medical necessity. Kevin Hern of Lilly USA told the same benefits symposium that the cost of covering the drugs depends partly on how sick patients are when they start, since people with advanced illness linked to obesity may lower other medical spending sooner. Lilly makes Mounjaro, so its view is not neutral. Plan sponsors also face the gap between list price and the net price they really pay after rebates, which our explainer on the four prices of one pen breaks down.

What workers and pharmacies should expect

Under the new Walmart GLP 1 coverage, the practical step for a worker with type 2 diabetes is the prior authorization. The zero price applies only after the plan approves a fresh request, so a prescriber will need to file the paperwork, and a short gap is possible early in 2027 if approvals lag. Pharmacies will see claims for Ozempic and Mounjaro split by diagnosis, with the same pen paid in full by the plan for one customer and rejected for another. Neither Walmart nor SHRM said how many employees take either drug today, so the number of people who gain from the change is not known. The benefit also depends on which medical plan an employee picks.

Workers who use the drugs only for weight loss keep paying out of pocket or go without. Lower cash prices set by the makers, such as the Wegovy cash price cut announced last year, are one legal route, and a doctor can explain the approved options. The gap also feeds demand for compounded copies and online sellers working at the edge of the rules, whose products can carry real quality risks. Our ratings score the change as high impact for patients and payers, moderate for prescribers, and low for pharmacies and sellers. Readers should treat the details as reported by SHRM, Reuters and Fox Business, since Walmart's full 2027 plan documents were not public when this story was written.

Conclusion

Walmart GLP 1 coverage for 2027 makes Ozempic and Mounjaro free for eligible workers with type 2 diabetes after a new prior authorization, while weight loss stays uncovered. The split matches what many US employers already do, as surveys show diabetes cover holding and obesity cover falling. The open questions are how many Walmart workers will qualify, how fast approvals move in January, and whether other large employers draw the same line this enrollment season. This story is news, not medical advice.